AZD 0284

Drug Profile

AZD 0284

Alternative Names: AZD0284

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Plaque psoriasis

Most Recent Events

  • 21 Feb 2017 Phase-I clinical trials in Plaque psoriasis (In volunteers) in United Kingdom (IV, Infusion) (NCT03029741)
  • 21 Feb 2017 Phase-I clinical trials in Plaque psoriasis (In volunteers) in United Kingdom (PO, Suspension) (NCT03029741)
  • 27 Jan 2017 AstraZeneca plans a phase I bioavailability trial in Healthy volunteers in United Kingdom (PO and IV) (NCT03029741)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top